dc.contributor.author | Cevit, O. | |
dc.contributor.author | Kendirli, S. G. | |
dc.contributor.author | Yilmaz, M. | |
dc.contributor.author | Altintas, D. U. | |
dc.contributor.author | Karakoc, G. B. | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T10:17:23Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T10:17:23Z | |
dc.date.issued | 2007 | |
dc.identifier.issn | 1018-9068 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/10716 | |
dc.description | WOS: 000250535800001 | en_US |
dc.description | PubMed ID: 17982919 | en_US |
dc.description.abstract | Background: Specific allergen immunotherapy (SIT) is the main treatment modality for achieving long-term symptom relief in perennial allergic diseases. Objective:The aim of this study was to evaluatethe effect of 1 year of house dust mite immunotherapy on the concentrations of 3 immunologic markers: eosinophil cationic protein (ECP), nitric oxide (NO), and monocyte chemoattractant protein 1 (MCP-1). We also compared the effect on asthma symptoms and medication scores, allergen-specific bronchial challenge test, and the skin prick test. Methods: A total of 31 mite-allergic, asthmatic children (age range, 6-16 years) were enrolled; 19 were treated with SIT and 12 controls who had refused SIT received only drug treatment. Efficacy was evaluated using serum NO, ECP, and MCP-11 levels, and asthma symptom and medication scores, allergen-specific bronchial challenge test, and skin-prick test. The results of the tests were compared at baseline and after 1 year of treatment. Results. Serum NO and ECP levels decreased significantly in the SIT group (P =.01 and P = .018) compared to baseline, whereas control group values remained similar The serum MCP-11 level decreased significantly in both the SIT and control groups (P = .009 and P = .041, respectively). The SIT group experienced significant improvement in asthma symptoms (P = .001) and medication scores (P = .001) and skin reactivity to Dermatophagoides pteronyssinus (P = .020), whereas the control group did not. The results of bronchial challenge to D pteronyssinus showed a similar pattern at baseline and after 1 year of treatment in both groups. The tolerated allergen concentration increased in both groups (P < .05). Lung function tests, total immunoglobulin (Ig) E and specific IgE to D pteronyssinus and Dermatophagoides farinae did not change after a year of treatment in either group. Conclusion: SIT with D pteronyssinus improves immunological and clinical parameters in mite-allergic asthmatic children after 1 year of treatment. The skin prick test may be used as a marker of efficacy of therapy. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | ESMON PUBLICIDAD S A | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | specific allergen immunotherapy | en_US |
dc.subject | asthma | en_US |
dc.subject | house dust mite | en_US |
dc.subject | childhood | en_US |
dc.title | Specific allergen immunotherapy: Effect on immunologic markers and clinical parameters in asthmatic children | en_US |
dc.type | article | en_US |
dc.relation.journal | JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY | en_US |
dc.contributor.department | Cumhuriyet Univ Fac Med, Dept Pediat, Div Allergy, TR-58140 Sivas, Turkey -- Cukurova Univ, Fac Med, Dept Pediat, Div Allergy, Adana, Turkey | en_US |
dc.identifier.volume | 17 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.endpage | 291 | en_US |
dc.identifier.startpage | 286 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |